TABLE 1.
Patient demographics and clinical characteristics.
| Characteristics |
Total (N = 289) No. of patients (%) |
FOLFIRI + Bevacizumab (N = 119) | FOLFIRI + Ramucirumab (N = 107) | FOLFIRI + Aflibercept (N = 63) | p value |
|---|---|---|---|---|---|
| Age at enrollment, years | |||||
| Median [range] | 63.0 [31.0–84.0] | 63.0 [32.0–82.0] | 64.0 [31–84.0] | 62.0 [43.0–80.0] | 0.87 |
| Sex | |||||
| Male | 137 (47.4) | 57 (47.9) | 46 (43.0) | 34 (54.0) | 0.39 |
| Female | 152 (52.6) | 62 (52.1) | 61 (57.0) | 29 (46.0) | |
| Primary site | |||||
| Right‐sided colon | 93 (32.2) | 39 (32.8) | 22 (20.6) | 17 (27.0) | 0.12 |
| Left‐sided colon | 196 (67.8) | 80 (67.2) | 85 (79.4) | 46 (73.0) | |
| Metastatic site | |||||
| Liver | 148 (51.2) | 58 (48.7) | 59 (55.1) | 31 (49.2) | 0.59 |
| Lung | 145 (50.2) | 66 (55.5) | 49 (45.8) | 36 (57.1) | 0.25 |
| Peritoneal | 97 (33.6) | 38 (31.9) | 31 (29.0) | 25 (39.7) | 0.34 |
| Lymph node | 99 (34.3) | 40 (33.6) | 40 (37.4) | 17 (27.0) | 0.38 |
| Other | 41 (14.2) | 14 (11.8) | 16 (15.0) | 11 (17.5) | 0.54 |
| RAS status in tissue | |||||
| Wild type | 134 (46.4) | 47 (39.5) | 57 (53.3) | 30 (47.6) | 0.11 |
| Mutant | 155 (53.6) | 72 (60.5) | 50 (46.7) | 33 (52.4) | |
| Prior bevacizumab exposure in first‐line chemotherapy | |||||
| Yes | 159 (55.0) | 68 (57.1) | 54 (50.5) | 37 (58.7) | 0.55 |
| No | 130 (45.0) | 51 (42.9) | 53 (49.5) | 26 (41.3) | |
| First‐line progression‐free survival (Patients treated with Bevacizumab only) | |||||
| ≤9 months | 71 (44.7) | 25 (36.8) | 29 (53.7) | 17 (45.9) | 0.16 |
| >9 months | 88 (55.3) | 43 (63.2) | 25 (46.3) | 20 (54.1) | |
| Patients who experienced relapse within 6 months of completing oxaliplatin‐based adjuvant therapy | |||||
| Yes | 40 (13.8) | 15 (12.6) | 15 (14.0) | 10 (15.9) | 0.84 |
| No | 249 (86.2) | 104 (87.4) | 92 (86.0) | 53 (84.1) | |
| Tumor markers (at initiation of second‐line chemotherapy) | |||||
| CEA median, [range] | 17.3 [0.5–17056.1] | 16.8 [1.0–1501.4] | 28.3 [0.5–17056.1] | 14.9 [1.0–7415] | 0.30 |
| CA19‐9 median, [range] | 32.7 [2.0–50000] | 27.6 [2.0–29210.2] | 33.0 [2.0–50000] | 33.6 [2.0–50000] | 0.71 |
| RAS:rat sarcoma viral oncogene homolog | |||||
| CEA: carcinoembryonic antigen | |||||
| CA19‐9: carbohydrate antigen 19–9 | |||||